Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The ...

Shares of Inovio Pharmaceuticals Inc. INO shed 1.03% to $1.92 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.52% ...

Shares of Inovio Pharmaceuticals Inc. INO shed 1.02% to $1.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.33% ...

Inovio plans to begin submitting the BLA for INO-3107 in mid-2025, with a goal of achieving FDA acceptance for filing by year-end 2025. Priority review will also be requested.

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

Citizens JMP lowered the firm’s price target on Inovio (INO) to $12 from $18 and keeps an Outperform rating on the shares. Inovio expressed ...

Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results ...

Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. Please note, this event is being recorded. Operator: Good day and welcome ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...